Q1 FY27 results: Revenue up 42% YoY, PAT jumps 49%; Rs 149 Cr capex approved
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts more than Nifty Microcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs posted strong Q1 FY27 results. Standalone revenue rose 42.5% YoY to Rs 534.59 Cr, PAT up 49.3% at Rs 71.31 Cr (EPS Rs 7.87). Consolidated revenue Rs 535.80 Cr, PAT Rs 76.14 Cr. Board approved Rs 149 Cr capex for a new Intermediate Block (405 KL capacity, 1 year timeline). Rashesh Gogri to become MD, Hetal Gogri Gala moves to Executive Director from Oct 1. Q1 FY26 figures were restated to recognise a fair value loss on an FX forward contract.
Strong quarterly growth and capacity expansion signal business momentum; management reshuffle and FX restatement are governance items to watch.